EUDA Health Holdings Limited (NASDAQ:EUDA) Short Interest Update

EUDA Health Holdings Limited (NASDAQ:EUDA) saw a significant decline in short interest in the month of April. As of April 15th, there was short interest totaling 4,737 shares, a decline of 22.3% from the March 31st total of 6,100 shares. Approximately 0.2% of the shares of the company are sold short. Based on an average daily trading volume, of 6,230 shares, the short-interest ratio is presently 0.8 days.

EUDA Health Trading Up 14.7%

NASDAQ:EUDA opened at $13.76 on Wednesday. EUDA Health has a 12-month low of $5.26 and a 12-month high of $86.00. The stock’s 50 day simple moving average is $10.99 and its 200-day simple moving average is $33.59. The firm has a market cap of $34.68 million, a P/E ratio of -5.57 and a beta of 0.17.

EUDA Health (NASDAQ:EUDA) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.44) earnings per share for the quarter, topping the consensus estimate of ($1.20) by $0.76. The company had revenue of $1.92 million for the quarter, compared to analyst estimates of $3.90 million. Research analysts forecast that EUDA Health will post -0.2 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in EUDA Health stock. Citadel Advisors LLC increased its position in shares of EUDA Health Holdings Limited (NASDAQ:EUDA) by 57.7% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 44,631 shares of the company’s stock after purchasing an additional 16,321 shares during the period. Citadel Advisors LLC owned approximately 0.12% of EUDA Health worth $78,000 as of its most recent SEC filing. 4.35% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

EUDA has been the subject of several research analyst reports. Weiss Ratings reissued a “sell (d)” rating on shares of EUDA Health in a report on Wednesday, April 8th. Greenridge Global decreased their price target on shares of EUDA Health from $120.00 to $55.00 and set a “buy” rating for the company in a research note on Monday, March 9th. Finally, Zacks Research downgraded shares of EUDA Health from a “hold” rating to a “strong sell” rating in a research report on Monday, March 23rd. One investment analyst has rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Reduce” and an average price target of $55.00.

About EUDA Health

EUDA Health, Inc (NASDAQ:EUDA) is a healthcare technology company focused on the development and commercialization of digital health solutions and energy-based medical devices for women’s intimate health. The company’s platform combines non-invasive treatment devices with software-driven patient monitoring and analytics to support pelvic floor function, address stress urinary incontinence and enhance vaginal tissue health.

EUDA Health’s core product offerings utilize low-intensity radiofrequency energy delivered through proprietary handpieces to promote tissue remodeling and muscle activation.